Literature DB >> 25632978

Influence of surface characteristics of modified glass beads as model carriers in dry powder inhalers (DPIs) on the aerosolization performance.

Sarah Zellnitz1, Hartmuth Schroettner2, Nora Anne Urbanetz1.   

Abstract

The aim of this work is to investigate the effect of surface characteristics (surface roughness and specific surface area) of surface-modified glass beads as model carriers in dry powder inhalers (DPIs) on the aerosolization, and thus, the in vitro respirable fraction often referred to as fine particle fraction (FPF). By processing glass beads in a ball mill with different grinding materials (quartz and tungsten carbide) and varying grinding time (4 h and 8 h), and by plasma etching for 1 min, glass beads with different shades of surface roughness and increased surface area were prepared. Compared with untreated glass beads, the surface-modified rough glass beads show increased FPFs. The drug detachment from the modified glass beads is also more reproducible than from untreated glass beads indicated by lower standard deviations for the FPFs of the modified glass beads. Moreover, the FPF of the modified glass beads correlates with their surface characteristics. The higher the surface roughness and the higher the specific surface area of the glass beads the higher is the FPF. Thus, surface-modified glass beads make an ideal carrier for tailoring the performance of DPIs in the therapy of asthma and chronically obstructive pulmonary diseases.

Entities:  

Keywords:  Fine particle fraction; glass beads; inhalation; surface area; surface roughness

Mesh:

Substances:

Year:  2015        PMID: 25632978     DOI: 10.3109/03639045.2014.997246

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  1 in total

Review 1.  Influence of physical properties of carrier on the performance of dry powder inhalers.

Authors:  Tingting Peng; Shiqi Lin; Boyi Niu; Xinyi Wang; Ying Huang; Xuejuan Zhang; Ge Li; Xin Pan; Chuanbin Wu
Journal:  Acta Pharm Sin B       Date:  2016-05-04       Impact factor: 11.413

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.